The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of ...

AstraZeneca’s campaign supporting its asthma and COPD treatment Breztri features several AI-generated elements.

AstraZeneca PLC (NYSE:AZN)’s breast cancer pill Etcamah (camizestrant) failed to meet the primary endpoint in the Phase III SERENA-4 trial, dealing a setback to one of the company’s key oncology ...

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales ...

Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche ...

A higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ...

SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a ...

An experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market ...

In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, ...

A committee said the volrustomig combination was unlikely to reach either of the primary endpoints for the trial, but the ...

AstraZeneca's breast cancer pill was authorized in an accelerated approval process, following an earlier vote against the ...

AstraZeneca Plc’s breast cancer pill failed to delay disease progression more than the standard treatment in a late-stage ...